Lovastatin Tablet
Product Images NDC 63629-3583

5 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lovastatin (NDC 63629-3583). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl636293583)

Label Image (Lbl636293583)
Label for Lovastatin 10 mg oral tablet by Bryant Ranch Prepack, in a package of 30 tablets. The label compares it to Mevacor 10 mg tablet by Carlsbad Technology Inc. The NDC is 63629-3583-1. It includes storage instructions at 20°-25°C (68°-77°F) and a warning not to use if pregnant.*
FDA Label Image

Structural Formula (Lov00 0004 01)

Structural Formula (Lov00 0004 01)
Chemical structure of Lovastatin. The diagram depicts the molecular structure with various atoms and bonds representing the active ingredient Lovastatin.*
FDA Label Image

Table I (Lov00 0004 02)

Table I (Lov00 0004 02)
Table showing the effect of other drugs on lovastatin exposure when co-administered. It lists drugs or grapefruit juice doses, lovastatin dosages, numbers of subjects, and area under the curve (AUC) ratios comparing lovastatin levels with and without co-administered substances.*
FDA Label Image

Figure 1 (Lov00 0004 03)

Figure 1 (Lov00 0004 03)
A line graph titled 'Acute Major Coronary Events (Primary Endpoint)' showing the proportion of participants without event over years of follow-up. Two lines represent Lovastatin and Placebo groups, with Lovastatin showing a higher proportion without events and a noted 37% risk reduction (p<0.001).*
FDA Label Image

Table Vii (Lov00 0005 04)

Table Vii (Lov00 0005 04)
A table titled 'Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis' lists interacting agents such as strong CYP3A4 inhibitors, HIV protease inhibitors, gemfibrozil, cyclosporine, and others. It provides prescribing recommendations for each, including contraindications and dose limitations related to lovastatin, as well as advice to avoid grapefruit juice.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.